RxDoctor Payments Data

Ido Preis, MD

Cardiovascular Disease · Boston, MANPI 1477729473

Payments from drug & device makers

$1,117in general payments, 2019–2025

Across 30 payments — averaging $37.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$376
  • Edwards Lifesciences$179
  • Boston Scientific$172
  • Heartflow, Inc.$149
  • Novartis$117
  • Abbott$28
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$1,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,117 in reported general payments places this provider in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$131,843
Medicare patients
1,578
Services billed
3,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$266,735
XareltoRivaroxaban34$45,041
EntrestoSacubitril/Valsartan17$30,623
JardianceEmpagliflozin31$27,337
FarxigaDapagliflozin Propanediol23$17,805
Praluent PenAlirocumab25$12,771
VascepaIcosapent Ethyl12$5,583
Metoprolol Succinate313$3,590
Atorvastatin Calcium271$2,667
Rosuvastatin Calcium145$1,577
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,478
Ezetimibe71$1,336
Flecainide Acetate26$1,262
Amiodarone Hcl46$1,211
Isosorbide Mononitrate ErIsosorbide Mononitrate82$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$24$45,04134 claims
NovartisEntresto$117$30,62317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →